A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Relapsed and/or Refractory Multiple Myeloma
DRUG: BMS-986453|DRUG: Fludarabine|DRUG: Cyclophosphamide
Number of participants with treatment-emergent adverse events (AEs), Up to 2 years|Number of participants with serious adverse events (SAEs), Up to 2 years|Number of participants with AEs leading to discontinuation, Up to 2 years|Number of participants with AEs leading to death, Up to 2 years|Number of participants with dose-limiting toxicities (DLTs), Up to 2 years
Maximum observed concentration (Cmax), Up to 2 years|Time of maximum observed concentration (Tmax), Up to 2 years|Area under the blood concentration-time curve from time zero to 28 days after dosing (AUC(0-28D)), Up to 2 years|Overall response rate (ORR), Up to 2 years|Complete response rate (CRR), Up to 2 years|Number of participants with very good partial response (VGPR) or better, Up to 2 years|Progression-free survival (PFS), Up to 2 years|Overall survival (OS), Up to 2 years|Time to response (TTR), Up to 2 years|Time to complete response (TTCR), Up to 2 years|Duration of response (DOR), Up to 2 years|Duration of complete response (DOCR), Up to 2 years|Persistence of BMS-986453 in peripheral blood, Defined as a transgene count greater than or equal to the lower limit of detection (LLOD), Up to 2 years|Expansion rate, Defined as Cmax divided by Tmax, Up to 2 years
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).